Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • William Blair Announces Acquisition of Inner Circle Sports

    William Blair today announced it has entered into a definitive agreement to acquire Inner Circle Sports, a leading boutique investment bank focused on the global sports, media, and entertainment ecosystem.

    Read more

  • REITs Repriced

    After years of underperformance, a rate backdrop and demand for tangible assets create a compelling setup across both deep value and capital-advantaged REITs.

    Watch the video

  • Trucking’s Tight Turn

    After years of overcapacity, supply is exiting trucking just as demand strengthens—driving rising rates, flatbed tightness, and potential upside to earnings into late 2026 and 2027.

    Watch the video
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures